1. Home
  2. ALMS
  3. ALMS News

Latest ALUMIS INC (ALMS) News on January 22, 2025

Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS),
ALMS

Simply Wall St.

25 days ago

Owning 32% shares,hedge funds owners seem interested in Alumis Inc. (NASDAQ:ALMS),

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
ALMS

GlobeNewswire

a month ago

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024
ALMS

GlobeNewswire

2 months ago

Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Convergence 2024

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
ALMS

GlobeNewswire

2 months ago

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
ALMS

GlobeNewswire

3 months ago

Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
ALMS

GlobeNewswire

4 months ago

Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study

Alumis to Participate in Upcoming September Investor Conferences
ALMS

GlobeNewswire

5 months ago

Alumis to Participate in Upcoming September Investor Conferences

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
ALMS

GlobeNewswire

5 months ago

Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
ALMS

GlobeNewswire

6 months ago

Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis

Share on Social Networks: